VRTX: Three White Soldiers detected on 2 Nov 2026

VRTX has formed a three white soldiers pattern at $558.88, the highest price point in today's movement. The structure score of 15.0/15 indicates pristine candle architecture, with the breakout score of 13.0/13 confirming clean upside momentum. Volume is elevated at 2.88M shares (2.08x average), supporting the advance. Resistance sits at $563.80 with key support established at $484.08. The overall score of 76.82/98 reflects a quality setup, though elevated volatility at 30.5% and overbought RSI at 67.65 warrant attention. The pattern emerges after a rounding bottom (March 2026) and weak bull flag (August 2026), suggesting accumulation over extended periods.

Vertex reports Q3 2026 earnings today (November 2, 2026) with analyst expectations of $3.4 billion revenue and $4.92 EPS. The company raised full-year 2026 revenue guidance to $13.1-$13.2 billion with a povetacicept PDUFA date of November 30th. Q2 2026 showed 12% YoY revenue growth driven by robust cystic fibrosis portfolio performance and newer products CASGEVY and JOURNAVX. The company entered an agreement to acquire Crinetics Pharmaceuticals in Q3 2026, adding rare endocrine diseases as a fifth revenue pillar. VRTX has topped EPS expectations in four consecutive quarters. The pattern timing coincides with earnings announcement, creating binary event risk alongside technical strength.

A successful breakout above $563.80 resistance would target the conservative measured move of $587.05, representing 4.9% upside from current levels. Volume confirmation is evident at 2.08x average, with elevated volatility (3.04% ATR) supporting potential for aggressive follow-through. The win probability score of 65.33% indicates better-than-baseline odds of success. Invalidation occurs on a close below key support at $484.08, representing 13.4% downside risk and defining the pattern's failure point. The pattern suggests momentum acceleration into results; historical data on three white soldiers shows highest reliability when coupled with elevated volume and trending sector conditions, both present here.

Critical near-term catalyst is Q3 earnings announcement occurring during pattern formation (today, Nov 2), creating substantial volatility risk post-close. FDA decision on povetacicept scheduled for November 30 introduces another binary event within weeks. RSI at 67.65 approaches overbought territory (70+), suggesting potential pullback risk. Broader market regime is bearish (-0.31) despite healthcare sector strength (+0.81), creating conflicting momentum headwinds. Beta of -0.12 indicates low market correlation, reducing portfolio diversification benefits but increasing single-stock risk. Volume ratio spike to 2.08x can signal capitulation or reversal; post-earnings volatility expansion could invalidate support levels rapidly. Crinetics acquisition closing uncertainty and elevated operating expenses near guidance high-end ($5.75B range) present execution risks to forward guidance.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.